3 models fit Mesa Laboratories Inc. Common Stock and they disagree: 0 of 3 land within 15% of the average.
Two or more of our models back this value.
Near fair value(i)Silver68
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, and Graham number.
ACCE opinionMesa Laboratories Inc. Common Stock (MLAB)
Fair value (3 models)
$123
ACCE price target
$139
Rating
Fairly valued
Horizon
12 months
Fair value published on 24 Oct 2026, 16:06 CEST; previously $134 since 17 Oct 2026, 00:00 CEST.
ACCE price target published on 14 Oct 2026, 00:00 CEST.
Rating published on 24 Oct 2026, 16:06 CEST.
Price used: $129 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
4.6% above
-4.4% to fair value
ACCE score
52
out of 100
Analysts
50% buy
2 covering
P/E
151.9x
forward 34.5x
1-year return
+63.5%
Dividend yield
0.50%
Mesa Laboratories Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Mesa Laboratories makes instruments for sterilization monitoring, cold-chain and environmental data loggers, and quality-control gear used in pharma and clinical labs, alongside a smaller bioscience and precision-measurement business. Its 64.2% gross margin is the most interesting number on the sheet, since it points to recurring consumables and validation services that sit on top of the hardware and carry pricing power. Revenue growth of 1.0% and a 2.7% ROE say the core business is currently going nowhere fast, and the 150x trailing P/E against a 34.5x forward P/E shows the market is paying for an earnings recovery that has not yet shown up in reported numbers. The thesis hinges on whether that margin structure can turn flat sales into operating leverage; until revenue re-accelerates, this is a name to watch for a turn in the top line rather than one to underwrite on current earnings.
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
high
Earnings collapsing despite flat revenue
Earnings fell 42.4% year over year while revenue grew only 1.0%, and net margin is just 1.9%. Operating margin of 11.7% is far below what the 64.2% gross margin implies, so costs are eating the profit.
high
Rich multiple on thin earnings
P/E of 147.2 on trailing earnings and EV/EBITDA of 20.1 leave little room for error.
moderate
Insider selling outweighs buying
Last 10 disclosed insider trades total $1.05M in sales against $0.90M in buys. Modest in size, but the net flow is negative.
moderate
Score drifting lower
ACCE score slipped 3 points over 90 days to 54, with growth at 19 and quality at 50. Short interest of 8.2% also signals some skepticism among traders.
AI research notes
AI-assisted·How I use AIWritten Oct 22, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Revenue has averaged growth of 13.2% per year over five years, a record that suggests the business has compounded well in the past.
Free cash flow of $40M over the last twelve months gives a 5.7% free cash flow yield at the current share price.
Why it could disappoint
Revenue grew just 1.0% over the last year, far below its five-year average, so the recent slowdown is clear.
Latest earnings per share came in at 2.21 against 2.55 expected, a 13.3% miss that undermines confidence in forecasts.
At a trailing P/E of 147.2x against a forward P/E of 34.5x and a sector median of 28.8x, the shares carry a steep premium.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where MLAB's valuation models land
Price
$128.66
Model fair value
$123
Model range
$58.57 to $259
Fair value $123
Price $129
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores